Direct anti-HCV agents
Unlike human immunodeficiency virus (HIV) and hepatitis B virus (HBV), hepatitis C virus (HCV) infection is a curable disease. Current direct antiviral agent (DAA) targets are focused on HCV NS3/4A protein (protease), NS5B protein (polymerase) and NS5A protein. The first generation of DAAs includes...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2016-01-01
|
| Series: | Acta Pharmaceutica Sinica B |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2211383515001409 |
| _version_ | 1811220899941056512 |
|---|---|
| author | Xingquan Zhang |
| author_facet | Xingquan Zhang |
| author_sort | Xingquan Zhang |
| collection | DOAJ |
| description | Unlike human immunodeficiency virus (HIV) and hepatitis B virus (HBV), hepatitis C virus (HCV) infection is a curable disease. Current direct antiviral agent (DAA) targets are focused on HCV NS3/4A protein (protease), NS5B protein (polymerase) and NS5A protein. The first generation of DAAs includes boceprevir and telaprevir, which are protease inhibitors and were approved for clinical use in 2011. The cure rate for genotype 1 patients increased from 45% to 70% when boceprevir or telaprevir was added to standard PEG-IFN/ribavirin. More effective and less toxic second generation DAAs supplanted these drugs by 2013. The second generation of DAAs includes sofosbuvir (Sovaldi), simeprevir (Olysio), and fixed combination medicines Harvoni and Viekira Pak. These drugs increase cure rates to over 90% without the need for interferon and effectively treat all HCV genotypes. With these drugs the “cure HCV” goal has become a reality. Concerns remain about drug resistance mutations and the high cost of these drugs. The investigation of new HCV drugs is progressing rapidly; fixed dose combination medicines in phase III clinical trials include Viekirax, asunaprevir+daclatasvir+beclabuvir, grazoprevir+elbasvir and others. |
| first_indexed | 2024-04-12T07:49:47Z |
| format | Article |
| id | doaj.art-23c5ab0918724f1080a0e154abc2298c |
| institution | Directory Open Access Journal |
| issn | 2211-3835 2211-3843 |
| language | English |
| last_indexed | 2024-04-12T07:49:47Z |
| publishDate | 2016-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Acta Pharmaceutica Sinica B |
| spelling | doaj.art-23c5ab0918724f1080a0e154abc2298c2022-12-22T03:41:37ZengElsevierActa Pharmaceutica Sinica B2211-38352211-38432016-01-0161263110.1016/j.apsb.2015.09.008Direct anti-HCV agentsXingquan ZhangUnlike human immunodeficiency virus (HIV) and hepatitis B virus (HBV), hepatitis C virus (HCV) infection is a curable disease. Current direct antiviral agent (DAA) targets are focused on HCV NS3/4A protein (protease), NS5B protein (polymerase) and NS5A protein. The first generation of DAAs includes boceprevir and telaprevir, which are protease inhibitors and were approved for clinical use in 2011. The cure rate for genotype 1 patients increased from 45% to 70% when boceprevir or telaprevir was added to standard PEG-IFN/ribavirin. More effective and less toxic second generation DAAs supplanted these drugs by 2013. The second generation of DAAs includes sofosbuvir (Sovaldi), simeprevir (Olysio), and fixed combination medicines Harvoni and Viekira Pak. These drugs increase cure rates to over 90% without the need for interferon and effectively treat all HCV genotypes. With these drugs the “cure HCV” goal has become a reality. Concerns remain about drug resistance mutations and the high cost of these drugs. The investigation of new HCV drugs is progressing rapidly; fixed dose combination medicines in phase III clinical trials include Viekirax, asunaprevir+daclatasvir+beclabuvir, grazoprevir+elbasvir and others.http://www.sciencedirect.com/science/article/pii/S2211383515001409Hepatitis C virusCure HCVSustained virologic responseDirect antiviral agentsNS3/4A protease inhibitor |
| spellingShingle | Xingquan Zhang Direct anti-HCV agents Acta Pharmaceutica Sinica B Hepatitis C virus Cure HCV Sustained virologic response Direct antiviral agents NS3/4A protease inhibitor |
| title | Direct anti-HCV agents |
| title_full | Direct anti-HCV agents |
| title_fullStr | Direct anti-HCV agents |
| title_full_unstemmed | Direct anti-HCV agents |
| title_short | Direct anti-HCV agents |
| title_sort | direct anti hcv agents |
| topic | Hepatitis C virus Cure HCV Sustained virologic response Direct antiviral agents NS3/4A protease inhibitor |
| url | http://www.sciencedirect.com/science/article/pii/S2211383515001409 |
| work_keys_str_mv | AT xingquanzhang directantihcvagents |